Seeking Alpha

Successful Phase 3 results for Xeljanz

  • In a 24-month 956-patient Phase 3 clinical trial, Pfizer's (PFE) rheumatoid arthritis (RA) drug Xeljanz demonstrated superior results over methotrexate in patients who had not previously taken methotrexate.
  • Xeljanz achieved its primary endpoint of statistically significantly superior results in inhibiting the progression of structural damage and reducing the signs and symptoms of RA compared to methotrexate at month six in patients with moderate-to-severe disease. The recommended dose is a 5 mg pill BID.
  • Xeljanz is a Janus-associated kinase (JAK) inhibitor that helps reduce RA symptoms such as joint pain, swelling and stiffness. It works by disrupting the signaling of cytokines related to the inflammation of RA.
  • The study results have just been published in the New England Journal of Medicine.
Comments (2)
  • cjhulin85
    , contributor
    Comment (1) | Send Message
     
    xeljanz is available at your local pharmacy for approx $2,485.00 for 60 tab. prescrip. taken twice daily. it better be a whole lot better than methotrexate.
    20 Jun, 11:43 AM Reply Like
  • jsijimmy
    , contributor
    Comments (286) | Send Message
     
    As always, i love these news updates - specifically: "...significantly superior results..." Sounds great, but please provide the data?! for all of you who don't know, in the world of pharma, 40-45% is passing - that is, if 40-45% of the patients in a trial react favorably to a drug, the drug is considered a success in the trial. So, if by "..significantly superior.." they mean xeljanz has a 50 or even 55% 'symptom reduction rate..." then I would say it is a success (assuming no bad side effects from using the drug)....please provide the data!

     

    Good investing!
    23 Jun, 08:26 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|